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Objective: The objective of this selective EBM review is to determine whether or not 
phonophoresis using NSAIDs reduces osteoarthritis knee pain. 
 
Study Design: Systematic review of three double-blind randomized controlled trials published 
between the years 2013 and 2018. 
 
Data Sources: Published peer-reviewed articles obtained through PubMed and Cochrane 
Collaboration. Articles were selected based on relevance to my clinical question and if they 
included patient-oriented outcomes. 
 
Outcomes Measured: Pain severity was self-reported by patients using a visual analog scale 
(VAS) on a continuum of 0-100; 0 representing no pain at all and 100 representing the worst 
pain imaginable. Participants in all three studies reported pain scores at baseline and after 
completing 2 weeks of treatment. 
 
Results: The study conducted by Luksurapan et al. showed a mean change from baseline of 
67%, a mean of between group difference of 14.73 +/- 5.78, and a P-value of 0.009.1 The study 
conducted by Monisha et al. showed a mean change from baseline of 70% and a P-value < 0.00.2 
The study conducted by Oktayoglu et al. showed a mean change from baseline of 23 and a P-
value of < 0.05.3  
 
Conclusion: All three studies in this EBM review demonstrated reduction of mild to moderate 
osteoarthritis knee pain with the use of phonophoresis using NSAIDs. Additional research may 
be indicated to further evaluate treatment outcomes with larger and more diverse patient 
populations, as well as long-term effects of treatment. 
 
Key Words: Phonophoresis, Osteoarthritis. 
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INTRODUCTION 
 Osteoarthritis (OA) is a chronic and progressive degenerative disease in which joint 
spaces are disrupted due to osteophytic lesions, subchondral sclerosis and cartilaginous 
erosions.2,3 Osteoarthritis is the most common cause of disability in adults and can lead to 
impairment in mobility, pain, and decreased quality of life.3,4 Hip and knee OA cause the greatest 
burden in terms of pain, stiffness, and functional disability, which may cause limitations in 
activities of daily living and the need for prosthetic joint replacements.2,4  
 Osteoarthritis is the most common joint disorder in the US and affects over 30 million 
adults; up to 13.5% of men and 18.7% of women.4 Etiology of OA may be multifactorial and 
some causes may include injuries, overuse of joints, increasing age, poor diet, obesity, genetics, 
female gender, congenital or developmental abnormalities, joint misalignment or muscle 
weakness.5 The incidence of OA is increasing, likely due to the aging population and the 
increased prevalence of obesity.4 OA accounts for approximately 11,127 office visits annually in 
the US.7 In 2012, osteoarthritis accounted for the highest cause of work loss, affecting more than 
20 million people in the work force and costing the US economy over $100 billion annually.4 In 
2013, knee osteoarthritis alone was estimated to contribute to over $27 billion in health care 
expenditures annually.4  
 The goal of treatment for knee OA is focused on pain relief, improving joint function, 
and modifying controllable risk factors.6 There are currently no disease modifying drugs 
available to treat OA, but there are multiple symptomatic treatment options available for 
improvement of pain and function.6 Nonpharmacologic treatment options include physical 
therapy, exercise, weight loss, walking aids and braces to alter joint loading.6 Pharmacological 
treatment options include topical non-steroidal anti-inflammatory drugs (NSAIDs), topical 
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Capsaicin cream, Acetaminophen, oral NSAIDs, oral Cyclooxygenase-2 (COX-2) inhibitors, 
intraarticular corticosteroids, and hyaluronic acid injections.6 Other treatment options include 
acupuncture, transcutaneous electrical nerve stimulator (TENS), ultrasound, iontophoresis, and 
surgery; total joint replacement and arthroscopic debridement.6 Using a combination of 
therapeutic approaches is preferred as drug options typically have more potential risk for adverse 
effects.6 
 Phonophoresis using NSAIDs may be used as an alternative treatment option for the 
reduction of osteoarthritis knee pain. Phonophoresis uses ultrasound to enhance percutaneous 
absorption of drugs.1 Ultrasound is a deep heating agent that can reduce pain by inducing tissue 
regeneration, reducing inflammation, and relaxing muscle tissue.1 Phonophoresis can use these 
therapeutic factors with the addition of NSAIDs, such as piroxicam or diclofenac 
dimethylamonium gel, to enhance reduction of pain and inflammation.1 This therapeutic method 
has the advantage of providing local treatment without the renal, cardiac, and gastrointestinal 
side effects of oral medications.3 Administration of topical NSAID agents can be used to 
maintain stable plasma levels while also maintaining a good safety profile.8 This paper evaluates 
three double-blind randomized controlled trials comparing the efficacy of phonophoresis using 
NSAIDs in the reduction of osteoarthritis knee pain. 
OBJECTIVE 
The objective of this selective evidence-based medicine (EBM) review is to determine 
whether or not phonophoresis using NSAIDs reduces osteoarthritis knee pain. 
METHODS 
 The articles selected for this systematic review include three double-blind randomized 
controlled trials. The population consists of patients with osteoarthritis knee pain. The treatment 
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group receiving phonophoresis using NSAID gel was compared to the experimental group 
receiving ultrasound with nonpharmacologic gel. Outcomes were measured using a visual analog 
scale (VAS) to assess the efficacy of phonophoresis with NSAIDs on the reduction of 
osteoarthritis knee pain. 
 “Phonophoresis” and “osteoarthritis” were the keywords used to find appropriate articles 
for this review through PubMed and Cochrane databases. All articles obtained were written in 
English and were published in peer reviewed journals between the years 2013 and 2018. Articles 
were selected based on their relevance to my clinical question and if they included patient-
oriented outcomes. Inclusion criteria included randomized control trials published after 2008 and 
studies evaluating osteoarthritis and phonophoresis using NSAIDs. Exclusion criteria included 




 Outcomes were measured using a visual analog scale, where pain severity was self-
reported by patients across a continuum on a scale of 0-100; 0 representing no pain at all and 100 
representing the worst pain imaginable. The VAS was completed at baseline and after two weeks 
of treatment to assess efficacy of the intervention compared to the control group. Outcomes were 
measured 2 days after the final treatment session to avoid short-term effects of heat application.1 
Additionally, the study completed by Oktayoglu et al.3 included further follow up at one, two, 
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Table 1: Demographics and characteristics of included studies 
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RESULTS 
 All three studies compared the efficacy of continuous phonophoresis with an NSAID 
based gel, either piroxicam or diclofenac diethylamonium, to nonpharmacologic ultrasound gel. 
Phonophoresis was generally well tolerated, without reports of any serious side effects. A total of 
10 sessions were completed, five times a week for two consecutive weeks for the duration of 10 
minutes each session. Studies conducted by Luksurapan et al. and Monisha et al. used ultrasonic 
wave frequency of 1 MHz and power of 1 W/cm2, whereas the study conducted by Oktayoglu et 
al. used a wave frequency of 1 MHz and power of 1.5 W/cm2.1,2,3 All three studies used the 
visual analog scale to evaluate a mean change from baseline and to obtain a P-value to determine 
statistical significance of phonophoresis compared to ultrasound in OA pain reduction.  
 The first study conducted by Luksurapan et al. was a double blind randomized controlled 
trial consisting of 45 females and 1 male between the ages of 26 and 78, with a median age of 59 
years.1 Each group being studied consisted of 23 individuals that fulfilled the American College 
of Rheumatology criteria for knee OA, Kellgren and Lawrence scores between I-III, and a VAS 
score > 50.1 Exclusion criteria is listed in Table 1. There were no significant differences between 
each group in terms of duration of knee pain, hours of weight-bearing activity, or Kellgren-
Lawrence scores.1 All participants in both study groups completed their allocated treatment 
without any dropouts.1 Everyone in the phonophoresis group completed all 10 treatment 
sessions, whereas 2 individuals in the ultrasound group completed 7 and 9 of the 10 treatment 
sessions.1 ANCOVA was used to adjust for the imbalance of treatment sessions attended.1 
Patients in the phonophoresis group received 20 mg of 0.5% piroxicam gel, whereas standard 
coupling gel was used in the control group.1 As seen in Table 2, both groups showed significant 
change in their VAS scores, indicating decreased OA knee pain.1 The phonophoresis group 
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presented with a significant reduction of pain and a mean change from baseline of 67% 
compared to the control group receiving ultrasound, with a mean change from baseline of 39%.1 
The mean of between group difference was 14.73 +/- 5.78 with a p-value of 0.009.1 While this 
data shows strong statistical significance, there is a wide 95% confidence interval (5.99-30.27), 
which may indicate a less precise estimate of the treatment effect due to a small sample size.1 
 
Table 2: Mean Change from Baseline and Statistical Significance, Luksurapan1 





70.57 +/- 12.03 23.57 +/- 19.27 
 
67% 0.009 




 The second study conducted by Monisha et al. was a double blind randomized controlled 
trial consisting of a total of 50 women between the ages of 40 and 70 years.2 Participants were 
randomly allocated to 3 different treatment groups, two of which are the focus of this review.2 
One group received phonophoresis with piroxicam gel and standard coupling gel in a 4:10 ratio, 
whereas the control group received ultrasound with an aquasonic gel.2 There was no mention of 
the number of individuals allocated to each treatment group or if there were any dropouts over 
the duration of this study. Inclusion criteria included a baseline VAS score of at least 10 and 
exclusion criteria is listed in Table 1. VAS scores of both groups, demonstrated in Table 3, show 
an improvement of mild to moderate OA knee pain when compared to baseline scores. The 
phonophoresis group showed a significant improvement of knee pain with a mean change from 
baseline of 70%, compared to the ultrasound group which showed a mean change from baseline 
of 50%.2 The p-value reported in this study was < 0.00, which indicates a strong statistical 
significance.2  
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Table 3: Mean Change from Baseline and Statistical Significance, Monisha2 
 Baseline Post-Treatment Mean Change from 
Baseline 
P-value 
Phonophoresis 75 25 
 
70% < 0.00 




The third study conducted by Oktayoglu et al. was a prospective randomized controlled 
trial consisting of 40 participants, 10 men and 30 women.3 The phonophoresis group consisted of 
13 women and 7 men with an average age of 54.55 +/- 8.65 years, whereas the ultrasound group 
consisted of 17 women and 3 men with an average age of 55.05 +/- 10.08 years.3 A non-treating 
author randomly allocated participants into each group, however there was no mention on 
whether or not patients, clinicians, and study workers were kept blind to treatment.3 All 
participants fulfilled the American College of Rheumatology criteria for knee osteoarthritis, had 
Kellgren-Lawrence scores between II-IV and VAS scores above 50.3 Exclusion criteria is listed 
in Table 1. There was not a significant difference in demographic data or pre-trial clinical 
parameters between the two study groups.3 The phonophoresis group received 1.16% diclofenac 
diethylamonium gel and the ultrasound group received a nonpharmacologic acoustic gel.3 VAS 
scores of walking, resting and flexion movement were obtained at baseline, post-treatment at 2 
weeks, and at one, two, and three months following treatment.3 There was no mention of 
dropouts over the duration of this study. For the purpose of this review, data in Table 4 presents 
walking VAS scores. As seen in Table 4, improvements were examined in VAS scores in both 
the phonophoresis and ultrasound groups during all follow up times.3 Both groups had 
comparable VAS scores from baseline to post-treatment at 2 weeks.3 At one month follow up, 
the phonophoresis group was shown to be superior to the ultrasound group when comparing 
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walking VAS scores, with a mean change from baseline of 23 compared to 10, respectively.3 
Statistical significance is demonstrated with a p-value of less than 0.05.3  
 
Table 4: Mean Change from Baseline and Statistical Significance, Oktayoglu3 
 Baseline Post-
Treatment 
1 month follow 
up 
2 month follow 
up 




64.5 +/- 14.68 52 +/- 12.81 
P-value: 0.002 
41.5 +/- 19.8 
P-value: 0.001 
47 +/- 22.73 
P-value: 0.002 
47.74 +/- 19.89 
P-value: 0.003 
Ultrasound 61 +/- 13.72 50 +/- 11.23 
P-value: 0.001 
51 +/- 11.19 
P-value: 0.003 
52.5 +/- 7.86 
P-value: 0.007 




 The objective of this systematic EBM review is to determine whether or not 
phonophoresis using NSAIDs reduces osteoarthritis knee pain. Each study used a visual analog 
scale to evaluate pain at baseline and after two weeks of treatment with either phonophoresis or 
nonpharmacologic ultrasound. Each study measured VAS outcomes two days after completion of 
treatment to avoid any short-term effects of heat application.1,2,3 The study conducted by 
Oktayoglu et al. additionally examined one, two, and three months follow up of treatment. This 
study showed promising results at one month follow up, but additional studies are needed to 
further evaluate long term effects of phonophoresis and to determine appropriate frequency of 
treatment. While this treatment option may be relatively inexpensive and well tolerated, there 
may be issues with poor compliance if patients are required to be present for treatment 5 days a 
week for two consecutive weeks. Phonophoresis should be administered for at least 10 minutes 
each session, as shorter application times have been proven to be ineffective.8 This may be a 
limitation to providers who do not have sufficient time or personnel to help administer this 
treatment effectively. 
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 Phonophoresis is noninvasive and simple to administer, which makes this treatment 
modality a great option for both patients and providers. While OA affects a wide range of 
patients, phonophoresis could be used in a variety of primary care settings, and not limited to 
physical therapy clinics. The sample size in all three studies ranged from 40-50 participants, 
which is relatively small. Evaluating larger experimental groups may be beneficial in assessing 
outcomes, as outliers in the study will not affect the results as much as they do in smaller sample 
sizes. The study conducted by Monisha et al. only examined female patients and the studies 
conducted by Luksurapan et al. and Oktayoglu et al. were female predominant. Studies have 
shown that male and female responses to treatment of pain may differ, indicating that the studies 
being reviewed in this paper may not have the ability to generalize these results to the general 
population.1  
Phonophoresis may be used to enhance transcutaneous delivery of NSAIDs to block 
nociceptive and neuropathic pain.8 One study determined that diclofenac had the smallest flow 
and permeability, when compared to ibuprofen 5% and piroxicam, making it more efficacious in 
pain reduction.8 Additional studies may be needed to determine which NSAID should be used to 
achieve maximum absorption and effectiveness. It may also be beneficial to have additional 
studies to compare outcomes using the same type of NSAID gel for phonophoresis in each 
experimental group. Luksurapan et al. and Monisha et al. used different ultrasound parameters in 
terms of power when compared to Oktayoglu et al., which could also facilitate different results in 
terms of percutaneous drug diffusion.1 Standardization of ultrasound wave frequency and power 
would help make these studies more comparable.  
According to the Food and Drug Administration (FDA), ultrasonic therapy devices must 
comply with medical device regulations and radiation safety performance standards, although 
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phonophoresis and ultrasonic diathermy devices have not been formally evaluated and 
approved.11 Phonophoresis is still considered experimental and investigational by insurance 
companies, which may limit coverage of this treatment and become a financial barrier to some 
patients. 
 Diclofenac gel is an approved treatment option for acute pain, osteoarthritis, and actinic 
keratosis.9 Skin irritation, including pruritis, contact dermatitis, application site pain, and 
desquamation, is a frequently reported side effect of this medication.9 Topical diclofenac gel is 
contraindicated in those with hypersensitivity to diclofenac or history of asthma, urticaria, or 
other allergic reactions to NSAIDs, open skin wounds, infections, or damaged skin.9 Other 
possible adverse reactions of topical diclofenac gel may include elevated liver function enzymes, 
gastrointestinal upset, and central nervous system effects such as headache, paresthesia, and 
hyperesthesia.9 Black box warnings for topical diclofenac include cardiovascular thrombotic 
events, gastrointestinal bleeding, ulceration, and perforation, although these risks are 
significantly lower than use of oral NSAIDs.6,9 NSAIDs should be avoided starting at 30 weeks 
of pregnancy due to risk of premature closure of fetal ductus arteriosus, although topical 
application of diclofenac crosses the placenta to a lesser extent than systemic use.9 It is unknown 
on whether or not use of topical diclofenac will be detected in breast milk, whereas it may be 
present with systemic use.9 Less information is given specifically for topical piroxicam, although 
breastfeeding is not recommended.10  
CONCLUSION 
 All three studies demonstrated conclusive evidence in short-term reduction of mild to 
moderate osteoarthritis knee pain with the use of phonophoresis using NSAIDs. Additional 
studies should to be completed to address limitations as mentioned and obtain more data 
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regarding this topic of study. Future experimental trials may benefit from evaluating treatment 
response from larger study groups and more diverse patient populations in terms of gender. From 
a clinical standpoint, it may also be beneficial to evaluate longer term effects of treatment. When 
non-pharmacological treatment options have failed or are no longer an option, oral NSAIDs, 
intraarticular steroids, and surgery are still some of the most commonly used treatments. 
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